A Blinded Study Comparing the Safety and Efficacy of a Fully Human Anti-IL8 Monoclonal Antibody (ABX-IL8) to Placebo in Patients With Chronic Bronchitis and COPD

• Status: Completed
• Trial end date: 2002-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine if ABX-IL8 will improve shortness of breath.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Abgenix

Criteria

Inclusion Criteria:

• > 50 years old

• > 20 pack-year of smoking

• Diagnosed with COPD and chronic bronchitis

Exclusion Criteria:

• Patients with bronchiectasis, cystic fibrosis, tuberculosis, asthma, alpha-1 antitrypsin deficiency, CHF

• Require oxygen therapy

• Uncontrolled hypertension

• HIV or Hepatitis

• Recent history of COPD exacerbation

• Patients with cancer

• Recent history of infection